Metro et al. enrolled 30 advanced NSCLC patients with EGFR Ex20ins; 15 patients received chemotherapy, and the other 15 received immunotherapy or chemo-immunotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.